Epicatechin’s cardiovascular protective effects are mediated via opioid receptors and nitric oxide
- 58 Downloads
Cardiovascular disease is the leading cause of mortality globally. Epicatechin has previously been shown to improve vascular responses and possess cardioprotective properties. However, the mechanisms underpinning these cardiotropic outcomes remain unknown. The aim of this study was to further identify epicatechin’s mechanism of action in the cardiovasculature.
The effects of epicatechin on isolated rat conduit arteries, resistance vessels and cardiac electrophysiology were investigated on resting tension and precontracted vessels and cardiac action potential parameters, both in the presence and in the absence of various antagonists.
At resting tension, epicatechin alone did not affect the vasoreactivity of either conduit or resistance vessels. In noradrenaline pre-contracted thoracic aortic arteries and potassium chloride pre-contracted mesenteric vessels, epicatechin (10−9–10−4 M) induced significant vasorelaxation. The addition of naloxone (10−5 M), NG-nitro-L-arginine methyl ester (10−5M), 4-aminopyridine (5 mM) and verapamil (10−5 M) attenuated epicatechin-mediated vasorelaxation. No change in epicatechin-mediated vasorelaxation was observed with the addition of atropine (10−5 M). Epicatechin significantly improved cardiac electrophysiology by reducing the resting membrane potential, action potential amplitude and force of contraction that was mitigated following the addition of naloxone (10−5 M). Epicatechin significantly decreased the action potential duration at 20, 50 and 90% duration and time to 90% relaxation of force that was unchanged following the addition of naloxone (10−5 M).
These findings suggest epicatechin’s vascular responses and cardioprotective effects are mediated through opioid receptors, nitric oxide, potassium channel and calcium channel activation and highlight the importance of the endothelium/nitric oxide in epicatechin mediated vasorelaxation.
KeywordsCardiovascular disease Epicatechin Flavonoids Nitric oxide Opioid receptors
The authors would like to thank Kieran Behan (Rockhampton Base Hospital, Rockhampton, Queensland, Australia) for providing the naloxone used in this study and the Office of Research Services, CQUniversity for providing the funding for this study.
Compliance with ethical standards
Ethical clearance for this Project was obtained from the Animal Ethics Committee of Central Queensland University (AEC# A14/11-321) and has, therefore, been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. The manuscript does not contain clinical studies or patient data.
Conflict of interest
The authors declare that they have no conflict of interest.
- 3.Willerson JT, Ridker PM (2004) Inflammation as a cardiovascular risk factor. Circulation 109(suppl II):II-2–II-10Google Scholar
- 9.Buijsse B, Feskens EJ, Kok FJ, Kromhout D (2006) Cocoa intake, blood pressure, and cardiovascular mortality: the Zutphen Elderly Study. Arch Intern Med 166(4):411–417Google Scholar
- 13.Gómez-Guzmán M, Jiménez R, Sánchez M, Zarzuelo MJ, Galindo P, Quintela AM, López-Sepúlyeda R, Romero M, Tamargo J, Vargas F, Pérez-Vizcaíno F, Duarte J (2012) Epicatechin lowers blood pressure, restores endothelial function, and decreases oxidative stress and endothelin-1 and NADPH oxidase activity in DOCA-salt hypertension. Free Radic Biol Med 52(1):70–79CrossRefGoogle Scholar
- 14.Engler MB, Engler MM, Chen CY, Malloy MJ, Browne A, Chiu EY, Kwak HK, Milbury P, Paul SM, Blumberg J, Mietus-Snyder ML (2004) Flavonoid-rich dark chocolate improves endothelial function and increases plasma epicatechin concentrations in healthy adults. J Am Coll Nutr 23(3):197–204CrossRefGoogle Scholar
- 17.Bhardwaj P, Khanna D (2013) Green tea catechins: defensive role in cardiovascular disorders. Chin J Nat Med 11(4):345–353Google Scholar
- 24.Gómez-Guzmán M, Jiménez R, Sánchez M, Romero M, O’Valle F, Lopez-Sepulveda R, Quintela AM, Galindo P, Zarzuelo MJ, Bailón E, Delpón E, Perez-Vizcaino F, Duarte J (2011) Chronic (−)-epicatechin improves vascular oxidative and inflammatory status but not hypertension in chronic nitric oxide-deficient rats. Br J Nutr 106(9):1337–1348CrossRefGoogle Scholar
- 25.Chen ZY, Yao XQ, Chan FL, Lau CW, Huang Y (2002) (−)Epicatechin induces and modulates endothelium-dependent relaxation in isolated rat mesenteric artery rings. Acta Pharmacol Sin 23(12):1188–1192Google Scholar
- 27.Panneerselvam M, Tsutsumi YM, Bonds JA, Horikawa YT, Saldana M, Dalton ND, Head BP, Patel PM, Roth DM, Patel HH (2010) Dark chocolate receptors: epicatechin induced cardiac protection is dependent on delta-opioid receptor stimulation. Am J Physiol Heart Circ Physiol 299(5):H1604–H1609CrossRefGoogle Scholar
- 30.Gross GJ, Peart JN (2007) Opioids and myocardial reperfusion injury. Arch Mal Coeur Vaiss 100:231–237Google Scholar
- 49.Al-Hasani A, Bruchas MR (2011) Molecular mechanisms of opioid receptor-dependent signalling and behaviour. Anesthesiology 115(6):1363–1381Google Scholar
- 55.Feuerstein TJ, Gleichauf O, Peckys D, Landwehrmeyer GB, Scheremet R, Jackisch R (1996) Opioid receptor-mediated control of acetylcholine release in human neocortex tissue. Naunyn-Schmiedeberg’s Arch Pharmacol 354:586–592Google Scholar
- 65.Lovegrove JA, Stainer A, Hobbs DA (2017) Role of flavonoids and nitrates in cardiovascular health. Proc Nutr Soc 19:1–13Google Scholar
- 66.Pokorney S, Piccini J (2017) Chocolate and prevention of atrial fibrillation: what is bad for the pancreas might be good for the atria? Heart. pii: heartjnl-2016-311026Google Scholar